IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

A Clinical Study of IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

This is a single-arm, single-center, open-label clinical study aimed at evaluating the safety and efficacy of IX001 TCR-T (T cell receptor-engineered T-Cell) injection in patients with advanced pancreatic cancer and colorectal cancer induced by KRAS (Kirsten Rat Sarcoma Viral Oncogene) mutations. A total of 6-18 evaluable patients are planned to be enrolled. The study will include 4 dose groups, using a '3+3' dose escalation design.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer; Pancreatic Cancer
• Intervention / Treatment: Biological: IX001 TCR-T cells

Detailed Description

Patients who sign the informed consent form will undergo screening based on inclusion/exclusion criteria. Eligible patients will be enrolled sequentially into dose group 1, dose group -1 or dose group 2, and dose group 3. The procedure of this study is as follows:

(I) The collected peripheral blood mononuclear cells (PBMCs) will be transported to the production workshop for the preparation of IX001. After confirming that IX001 is proved qualified, the investigator will decide whether to start pre-conditioning 5 days before IX001 infusion.

(II) TCR-T cells will be administered via intravenous infusion, and the cell infusion dose will be determined according to the requirements of dose escalation.

(III) Following TCR-T cell infusion, recombinant human interleukin-2 (IL-2) will be continuously injected to assist TCR-T cell growth.

(IV) After TCR-T cell infusion and IL-2 injection are completed, safety and efficacy follow-up visits will be conducted with the subjects until week 96 or until the subject prematurely withdraws from the study.

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: MingHua Yu, Dr.; Phone Number: 18017821601; Email: minghua_md@fudan.edu.cn
• Study Contact Backup: Name: ZhiGuo Long, M.D.; Phone Number: 18117253161; Email: zglong1976@126.com

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China
      • Recruiting
      • Shanghai Pudong Hospital
      • Contact: Minghua Yu, Dr.; Email: minghua_md@fudan.edu.cn
      • Contact: Zhiguo Long, M.D.; Email: zglong1976@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Voluntary signing of an informed consent form (ICF);
2. Males or females, aged 18-70 years (inclusive);
3. Pathologically diagnosed with advanced pancreatic cancer or colorectal cancer, having failed or intolerant to at least two lines of standard of care, including metastatic tumors (having received conventional chemotherapy), recurrent tumors (having undergone surgery and adjuvant chemotherapy in the past), or locally advanced tumors with disease progression after neoadjuvant treatment;
4. At least one measurable lesion (according to RECIST1.1[The Response Evaluation Criteria In Solid Tumors] criteria);
5. Patients with tumor tissue or peripheral blood testing positive for KRAS-G12V or G12D mutations and expression of matching HLA-A*11, C*01:02, or C*08:02 subtypes;
6. ECOG (Eastern Cooperative Oncology Group)≤2;
7. Life expectancy ≥3 months;
8. Absolute neutrophil count ≥1×10E9/L;
9. Platelet count ≥50×10E9/L, hemoglobin>90g/dL;
10. Absolute lymphocyte count ≥0.5×10E9/L;

11. Adequate functional reserve of organs:

    1. Aspartate aminotransferase ≤2.5×ULN (upper limit of normal);
    2. Aspartate transaminase ≤2.5×ULN;
    3. Creatinine clearance ≥60mL/min;
    4. Total serum bilirubin ≤1.5×UNL;
    5. The subject has left ventricular ejection fraction (LVEF) ≥ 50% and no clinically significant pericardial effusion diagnosed by echocardiography;
    6. No clinically significant electrocardiographic abnormality;
    7. Basic oxygen saturation is >92% under the indoor natural air environment.
12. Women of childbearing age must be negative for blood HCG (Human Chorionic Gonadotropin) pregnancy test (by immunofluorescence method) at screening and baseline periods, and agree to use effective contraception for at least 1 year after infusion; and male subjects whose partners are women of childbearing age must agree to use effective barrier contraception methods and avoid sperm donation for at least 1 year after infusion. Contraception must include one highly effective and one additional effective (barrier) method, initiated from screening until at least 1 year after IX001 infusion or until two consecutive flow cytometry tests show the absence of TCR-T cells (whichever occurs later).

Exclusion Criteria:

1. Other malignancies (except non-melanoma skin cancer with the disease-free survival of more than 5 years and cervical carcinoma in situ, bladder cancer, or breast cancer);
2. A history of mental disorders, which may affect compliance with this protocol or lead to failure in signing the ICF;
3. Poorly controlled hypertension with drug (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or occurrence of grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stent placement, unstable angina pectoris, or other clinically significant heart diseases within one year prior to signing the ICF; QTc interval >450 ms for males or QTc interval >470 ms for females during screening (QTc interval calculated using the Fridericia formula);
4. Presence of any indwelling catheter or drainage tube (e.g., percutaneous nephrostomy tube, indwelling catheter, bile drainage tube or pleural/peritoneal/pericardial catheter), except any dedicated central venous catheter;
5. A history of or any central nervous system disorders, such as epileptic seizure, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving the central nervous system;

6. A positive result obtained in any of the following virological tests:

   1. Antibody to human immunodeficiency virus (HIV antibody);
   2. Hepatitis C virus antibody (HCV antibody), with a positive result for hepatitis C virus ribonucleic acid (HCV RNA);
   3. Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) copies;
   4. Treponema pallidum antibody (TP antibody); patients may be enrolled after additional examinations are performed to exclude active syphilis where necessary;
7. Fungal, bacterial, viral or other infections or suspected fungal, bacterial, viral or other infections that cannot be controlled or require intravenous administration;
8. Significant tendency for bleeding, such as active gastrointestinal bleeding, coagulation disorders;
9. Patients with a history of severe allergy or allergic constitution;
10. A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis and systemic lupus erythematosus) requiring systemic immunosuppressive/systemic disease-modulating drugs in the past 2 years;
11. Interstitial lung disease (such as pneumonia, pulmonary fibrosis), or a history of clinically significant respiratory system diseases during screening;
12. History of organ transplantation;
13. Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 2 weeks prior to leukapheresis;
14. Receipt of gene therapy or other cell therapies with the same target within the past 6 months;
15. Participation in any other clinical trial within 4 weeks prior to signing the informed consent form, or the date of signing the informed consent form still within 5 half-lives of the drug from the last dose in the last clinical trial (whichever is longer);
16. Patients with poor compliance due to physiological, family, social, geographic and other factors, and failure to follow the study protocol and the follow-up plan;
17. Patients with contraindications to cyclophosphamide, fludarabine, IL-2, or other drugs related to the study treatment;
18. Comorbidities requiring treatment with systemic corticosteroids (dexamethasone at a dose of ≥5 mg/day or other corticosteroids at the equivalent dose) or other immunosuppressive drugs within 12 weeks after the study treatment starts as judged by the investigator;
19. Women who are breastfeeding and are unwilling to stop breastfeeding;
20. Any other conditions that are, in the opinion of the investigator, not suitable for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IX001 TCR-T cells; IX001 TCR-T cells targeted for KRAS mutation	Biological: IX001 TCR-T cells; IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose-limiting Toxicity (DLT)	Proportion of patients with DLT	4 weeks
Adverse Events (AEs)	Incidence and severity of adverse events	96 weeks
Serious Adverse Events (SAEs)	Incidence and severity of serious adverse events	96 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR)	The percentage of participants who achieved Complete Response (CR) or Partial Response (PR) based on RECIST version 1.1	12 weeks
Disease Control Rate (DCR)	The percentage of participants who achieved Complete Response (CR) or Partial Response (PR) or Stable disease (SD) based on RECIST version 1.1	12 weeks
Changes in Serum Tumor Markers compared to Baseline	Changes of tumor markers in serum detected by immunofluorescence compared to baseline level, including carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 12-5 (CA12-5)	12 weeks
Duration of response (DOR)	DOR is defined as the time from the first evaluation of a tumor as CR or PR to the first evaluation as PD or death from any cause	96 weeks
Time to response (TTR)	TTR is defined as the time between cell infusion and initial disease assessment as CR or PR	96 weeks
Progression-free survival (PFS)	PFS is defined as the time from the date of cell infusion until the date of tumor progression or death from any cause	96 weeks
Overall survival (OS)	OS is defined as the time between the date of cell infusion and the death of the patient for any reason	96 weeks
TCR gene copies	TCR gene copies detected by qPCR in peripheral blood	96 weeks
TCR-T cell counts	TCR-T cell counts detected by flow cytometry in peripheral blood	96 weeks
Proportion of patients with anti-IX001 antibodies in peripheral blood	Anti-drug Antibodies	96 weeks

Collaborators and Investigators

• Sponsor: Shanghai Pudong Hospital
• Collaborators: ImmuXell Biotech Ltd.
• Investigators: Principal Investigator: MingHua Yu, Dr., Shanghai Pudong Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2024
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: June 7, 2024
• First Submitted That Met QC Criteria: July 2, 2024
• First Posted (Actual): July 5, 2024

Study Record Updates

• Last Update Posted (Actual): July 5, 2024
• Last Update Submitted That Met QC Criteria: July 2, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: KRAS-G12V or G12D
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Endocrine Gland Neoplasms; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Pancreatic Diseases; Colorectal Neoplasms; Pancreatic Neoplasms
• Other Study ID Numbers: BT003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No